TAOK1 regulates chemo- and radiosensitivity in BRCA1/2-deficient tumors

Authors:
  • LLLea Lingg
    Lea Lingg
  • MMMerve Mutlu
    Merve Mutlu
  • ANArunasalam Naguleswaran
    Arunasalam Naguleswaran
  • IKIsmar Klebic
    Ismar Klebic
  • EGEwa Gogola
    Ewa Gogola
  • DSDilara Akhoundova Sanoyan
    Dilara Akhoundova Sanoyan
  • PSPascale Martine Schürch
    Pascale Martine Schürch
  • RKRaviprasad Kuthethur
    Raviprasad Kuthethur
  • CFCarmen Fonseca
    Carmen Fonseca
  • SBSimone de Brot
    Simone de Brot
  • MEMarieke Everts
    Marieke Everts
  • MGMartín González-Fernández
    Martín González-Fernández

Abstract
BRCA1/2-deficient cells are hypersensitive to replication stress- and DNA-damage-inducing agents such as poly(ADP-ribose) polymerase inhibitors (PARPi), platinum drugs, and ionizing radiation (IR), largely due to impaired homologous recombination repair and replication fork (RF) protection. The precise mechanisms underlying RF vulnerability in the absence of BRCA1/2 remain incompletely understood, however. Here, we identify Thousand And One Amino Acid Kinase 1 (TAOK1) as a novel regulator of RF dynamics that sensitizes BRCA1/2-deficient cells to both PARPi and IR. Unlike established DNA repair factors, such as PARG or the 53BP1-RIF1-shieldin-CST pathway, which mediate PARPi sensitivity while protecting cells against IR, TAOK1 promotes RF degradation and suppresses post-replicative damage repair. TAOK1 depletion stabilizes RFs and reduces replication-associated DNA damage in BRCA1/2-deficient cells, thereby conferring therapy resistance. Interestingly, we found that TAOK1 functions in RF regulation to be independent of its kinase activity. Instead, it interacts with PCNA and regulates ISG15 levels and thereby affects RF stability. Our findings reveal TAOK1 as a non-canonical mediator of therapy sensitivity in BRCA1/2-deficient tumors. Teaser: TAOK1 controls replication fork stability through PCNA and ISG15, affecting therapy response in BRCA1/2-deficient cancers.
Funding Information
  • Swiss National Science Foundation (grant 320030M_219453 (JJ, SR))
  • European Research Council (grant ERC-2019-AdG-883877 (SR))
  • Swiss Cancer Research Foundation (grant KFS-5519-02-2022 (SR))
  • Office of the Assistant Secretary of Defense for Health Affairs through the Ovarian Cancer Research Program (Award No. W81XWH-22-1-0557 (SR))
  • ISREC Foundation grant ((SR))
  • Foundation for Clinical-Experimental Cancer Research ((PF))